Company Filing History:
Years Active: 2006
Title: Kaoji Higashio: Innovator in Metabolic Bone Disease Diagnosis
Introduction
Kaoji Higashio is a prominent inventor based in Saitama, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the diagnosis of metabolic bone diseases. His innovative work has led to the development of a patented method that enhances the understanding and diagnosis of conditions such as osteoporosis and arthrosis.
Latest Patents
Higashio holds a patent for a method of diagnosing metabolic bone diseases. This method is characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. The patent includes the use of monoclonal antibodies that recognize both the monomer and dimer types of OCIF. Additionally, it features monoclonal antibodies that selectively recognize the dimer type of OCIF. The patent also provides an assay kit for determining OCIF concentration, which comprises the aforementioned antibodies that recognize different epitopes of OCIF and exhibit high affinity, with a dissociation constant of less than 2×10M with the antigen. This innovation is particularly useful for diagnosing metabolic bone diseases and serves as an assay reagent for related research.
Career Highlights
Kaoji Higashio is associated with Sankyo Company, Limited, where he has been able to apply his expertise in medical diagnostics. His work has been instrumental in advancing the methodologies used in the diagnosis of bone-related diseases. His dedication to research and innovation has positioned him as a key figure in his field.
Collaborations
Higashio has collaborated with notable colleagues, including Kazuki Yano and Fumie Kobayashi. These collaborations have further enriched his research and contributed to the development of effective diagnostic tools.
Conclusion
Kaoji Higashio's contributions to the diagnosis of metabolic bone diseases through his patented methods highlight his role as an innovator in the medical field. His work continues to impact the way these diseases are diagnosed and understood, paving the way for future advancements in medical diagnostics.